Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaume Capdevila

Showing results (141-150 of 192) with videos related to

Pageof 20
Sort By:
Endocrine-Related Cancer|April 11, 2025
Spanish consensus on the diagnosis and management of adrenocortical carcinomaMarta Araujo-Castro, Cristina Álvarez-Escola, Ana Casteràs, et al.
Lancet (London, England)|June 8, 2024
[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 studySimron Singh, Daniel Halperin, Sten Myrehaug, et al.
JAMA Oncology|August 30, 2019
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical TrialCarlos Fernández-Martos, Carles Pericay, Ferran Losa, et al.
British Journal of Cancer|September 4, 2019
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)Mª Pilar Solis-Hernandez, Ana Fernandez Del Valle, Alberto Carmona-Bayonas, et al.
Cancer Medicine|December 19, 2019
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)Jaime Feliu, Rocio Garcia-Carbonero, Jaume Capdevila, et al.
Translational Oncology|April 9, 2023
Impact of the COVID-19 pandemic in the early-onset colorectal cancerIosune Baraibar, Ariadna García, Francesc Salvà, et al.
Molecular Cancer Therapeutics|September 5, 2021
A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine PathwayMelanie Wurm, Otmar Schaaf, Katharina Reutner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2019
Epigenetic <i>EGFR</i> Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine CarcinomasJaume Capdevila, Oriol Arqués, Jose Ramón Hernández Mora, et al.
Thyroid : Official Journal of the American Thyroid Association|August 19, 2025
Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in <i>RET</i>-Mutant Medullary Thyroid CancerRossella Elisei, Lori J Wirth, Jaume Capdevila, et al.
Scientific Reports|April 2, 2021
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumabLucía Trilla-Fuertes, Angelo Gámez-Pozo, Joan Maurel, et al.
Pageof 20

Showing results (141-150 of 192) with videos related to

Sort By:
Pageof 20
Endocrine-Related Cancer|April 11, 2025
Spanish consensus on the diagnosis and management of adrenocortical carcinomaMarta Araujo-Castro, Cristina Álvarez-Escola, Ana Casteràs, et al.
Lancet (London, England)|June 8, 2024
[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 studySimron Singh, Daniel Halperin, Sten Myrehaug, et al.
JAMA Oncology|August 30, 2019
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical TrialCarlos Fernández-Martos, Carles Pericay, Ferran Losa, et al.
British Journal of Cancer|September 4, 2019
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)Mª Pilar Solis-Hernandez, Ana Fernandez Del Valle, Alberto Carmona-Bayonas, et al.
Cancer Medicine|December 19, 2019
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)Jaime Feliu, Rocio Garcia-Carbonero, Jaume Capdevila, et al.
Translational Oncology|April 9, 2023
Impact of the COVID-19 pandemic in the early-onset colorectal cancerIosune Baraibar, Ariadna García, Francesc Salvà, et al.
Molecular Cancer Therapeutics|September 5, 2021
A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine PathwayMelanie Wurm, Otmar Schaaf, Katharina Reutner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2019
Epigenetic <i>EGFR</i> Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine CarcinomasJaume Capdevila, Oriol Arqués, Jose Ramón Hernández Mora, et al.
Thyroid : Official Journal of the American Thyroid Association|August 19, 2025
Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in <i>RET</i>-Mutant Medullary Thyroid CancerRossella Elisei, Lori J Wirth, Jaume Capdevila, et al.
Scientific Reports|April 2, 2021
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumabLucía Trilla-Fuertes, Angelo Gámez-Pozo, Joan Maurel, et al.
Pageof 20